clinical trials using adenovirus vectors gene transfer airways cystic fibrosis cf patients progress little known prevalence adenovirus infections patients cystic fibrosis effect lung function answer questions serum igg igm antibody titers adenovirus type NUMBER prospectively measured indirect immunofluorescence assay NUMBER cf outpatients control group NUMBER healthy children young adults addition performed pulmonary function tests patients stable clinical condition igm antibodies adenovirus present NUMBER NUMBER cystic fibrosis patients NUMBER igg antibodies adenovirus detected NUMBER NUMBER cystic fibrosis patients NUMBER significantly higher cystic fibrosis patients older NUMBER years younger patients age matched controls igg antibody titers measured second time NUMBER months later NUMBER NUMBER patients increased NUMBER NUMBER patients NUMBER NUMBER patients increase antibody titer fvc fev1 decreased NUMBER p NUMBER NUMBER p NUMBER respectively NUMBER months comparison group matched age sex chronic pseudomonas aeruginosa infection increase antibody titers fvc fev1 unchanged results indicate adenovirus infections prevalent cystic fibrosis patients adenovirus infections cystic fibrosis patients associated deterioration lung function observations important implications efficacy safety considerations using adenoviral vectors gene therapy replication deficient wild type NUMBER fold wild type wild type